COMMUNIQUÉS West-GlobeNewswire

Tyme to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
13/11/2017
NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq: TYME ), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that Jonathan Eckard, Chief [...]
Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
13/11/2017
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) announced today that the independent Data and Safety Monitoring Board (DSMB) for the Phase 3 HOPE ( H [...]
Clinical Genomics and Quest Diagnostics announce FDA 510(K) clearance of InSure® ONE™
13/11/2017
At-home collection, one-day fecal immunochemical test that meets American Cancer Society guidelines and HEDIS quality measures for lower gastrointestinal bleeding screening programs A number of medical conditions may be [...]
Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer
13/11/2017
NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced [...]
Clementia annonce ses résultats financiers et les faits saillants du troisième trimestre 2017
13/11/2017
Premier appel public à l’épargne achevé générant un produit net de 128,2 M$ La FDA des États-Unis accorde la désignation de traitement révolutionnaire au palovarotene contre la fibrodysplasie ossifiante progressive (FOP [...]
Clementia Reports Third Quarter 2017 Financial Results and Business Highlights
13/11/2017
Initial Public Offering Completed, Raising $128.2 Million in Net Proceeds U.S. FDA Grants Breakthrough Therapy Designation to Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP) On Track to Begin Pivotal MOVE [...]
Le personnel infirmier du Canada célèbre la Semaine nationale des infirmières et des infirmiers praticiens en lançant un projet visant à augmenter les soins dispensés par les IP afin de répondre aux besoins croissants
13/11/2017
OTTAWA, 13 nov. 2017 (GLOBE NEWSWIRE) -- Afin de célébrer la Semaine nationale des infirmières et des infirmiers praticiens (IP), qui se tiendra du 12 au 18 novembre, le personnel infirmier du Canada lance un projet de [...]
Canada’s nurses celebrate National Nurse Practitioner Week by launching a project to expand NP care to meet growing need
13/11/2017
OTTAWA, Nov. 13, 2017 (GLOBE NEWSWIRE) -- In celebration of National Nurse Practitioner (NP) Week taking place from November 12 to 18, Canada’s nurses are launching a retention and recruitment project aimed at [...]
Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
13/11/2017
FDA Clears Phase 3 Protocol for Patient Enrollment in GBM Brain Cancer Trial “First Patient In” Expected this Year Company Charter Amendment Addresses Nasdaq Listing Issue Additions to Board and Management Strengthen [...]
CymaBay Therapeutics to Present at Three Investor Conferences
13/11/2017
NEWARK, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]
Iovance Biotherapeutics to Present at the Jefferies 2017 London Healthcare Conference
13/11/2017
SAN CARLOS, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) [...]
CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer
13/11/2017
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, [...]
Emerald Health Therapeutics Announces Positive Health Canada Review of its Licensed Producer Application for Pure Sunfarms Facility
13/11/2017
RICHMOND, British Columbia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (TSXV:EMH) (OTCQX:EMHTF) announced today that its licensed producer application for the Pure Sunfarms Delta 3 greenhouse [...]
Interpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent Accomplishments
13/11/2017
Q3-2017 Net Revenues of Over $4 Million Growing 27% Over Prior Year Quarter Represents Fourth Straight Quarter of Sequential Revenue Growth Net Loss for the Quarter & Year to Date a 56% and 51% Improvement Over [...]
Novo Nordisk A/S - Share repurchase programme
13/11/2017
Bagsværd, Denmark, 13 November 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Reata Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial and Operating Results
13/11/2017
IRVING, Texas, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA ) (Reata or Company), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended [...]
ProMIS Neurosciences Announces Third Quarter 2017 Results
13/11/2017
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, [...]
Actinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail Roboz
13/11/2017
- Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell Medical College and NewYork-Presbyterian will introduce the planned clinical initiative on the webcast - Webcast to be held [...]
Clearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting
13/11/2017
ALPHARETTA, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, [...]

Pages